Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.

[1]  M. Cairo,et al.  Allogeneic cellular and autologous stem cell therapy for sickle cell disease: ‘whom, when and how’ , 2012, Bone Marrow Transplantation.

[2]  S. Spellman,et al.  Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  J. Jacobson,et al.  T cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients , 2012, British journal of haematology.

[4]  J. Jacobson,et al.  A comparison of immune reconstitution and graft‐versus‐host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients , 2011, British journal of haematology.

[5]  L. Shaw,et al.  A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents , 2011, Bone Marrow Transplantation.

[6]  L. Shaw,et al.  An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  Zhezhen Jin,et al.  Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  J. Wagner,et al.  Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  M. Cairo,et al.  Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases , 2007, Bone Marrow Transplantation.

[10]  M. Cairo,et al.  Cord blood immunology and stem cell transplantation. , 2005, Human immunology.